|

Trastzumab Deruxtecan Clinical Trials

1 actively recruiting trial

Also known as: DS-8201, Enhertu, T-DXd

Pipeline

Phase 2: 1

Top Sponsors

  • Yonsei University1

Indications

  • Ovarian Cancer Metastatic Recurrent1
  • Ovarian Cancer (OvCa)1
  • Ovarian Carcinoma, Recurrent1
  • Ovarian Cancer1
  • Cancer1

Other1 trial

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.